Lp-PLA2 Inhibition-The Atherosclerosis Panacea?

Area of Science:

• Cardiovascular Medicine
• Biomarker Discovery
• Pharmacology

Background:

• Atherosclerosis pathophysiology involves multiple factors, leading to the investigation of numerous biomarkers for risk stratification and therapeutic targeting.
• Lipoprotein-associated phospholipase A2 (Lp-PLA₂) has emerged as a significant lipid-associated biomarker due to its role in generating pro-inflammatory compounds from oxidized LDL.

Approach:

• Epidemiological studies and clinical trials have consistently linked increased Lp-PLA₂ levels to higher cardiovascular risk and endothelial dysfunction.
• Experimental data in animal models suggest Lp-PLA₂ inhibition can modulate vulnerable plaque phenotypes.
• Clinical studies in patients with coronary heart disease (CHD) show Lp-PLA₂ inhibition positively affects inflammatory markers and can retard necrotic core progression.

Key Points:

• Increased Lp-PLA₂ mass or activity is associated with increased cardiovascular risk and may improve risk stratification.
• Lp-PLA₂ plays a role in plaque vulnerability and progression, particularly the necrotic core.
• A specific Lp-PLA₂ inhibitor shows promise as a therapeutic agent, with ongoing Phase 3 trials.

Conclusions:

• Lp-PLA₂ is a valuable biomarker for assessing cardiovascular risk and identifying patients who may benefit from targeted therapy.
• Inhibition of Lp-PLA₂ offers a potential strategy to reduce residual cardiovascular risk in high-risk patients, even those on polypharmacotherapy.